

RECEIVED
CENTRAL FAX CENTER
DEC 12 2007



Fort Lauderdale
Jacksonville
Los Angeles
Madison
Miami
New York
Orlando
Tallahassee
Tampa
Tysons Corner
Washington, DC
West Palm Beach

Esperanto Building
222 Lakeview Avenue, Suite 400
West Palm Beach, Florida 33401-6183
Post Office Box 3188 *mail*
West Palm Beach, Florida 33402-3188
www.akerman.com
561 653 5000 *tel* 561 659 6313 *fax*

FAX COVER SHEET

From: Nicholas J. Landau, Ph.D.

Date: December 12, 2007

PLEASE DELIVER 4 PAGE(S) (including cover sheet) TO:

Name:

Fax Number: 571-273-8300

Company: United States Patent and Trademark Office

Phone Number:

Please call (561) 653-5000, Ext. 30005 if you do not receive all the pages.

Comments/Special Instructions

Please file attached.

CONFIDENTIALITY NOTE: The information contained in this transmission may be privileged and confidential information, and is intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this transmission in error, please immediately reply to the sender that you have received this communication in error and then delete it. Thank you.

CIRCULAR 230 NOTICE: To comply with U.S. Treasury Department and IRS regulations, we are required to advise you that, unless expressly stated otherwise, any U.S. federal tax advice contained in this transmittal, is not intended or written to be used, and cannot be used, by any person for the purpose of (i) avoiding penalties under the U.S. Internal Revenue Code, or (ii) promoting, marketing or recommending to another party any transaction or matter addressed in this e-mail or attachment.

Client/Matter No: 40717/174504

User ID: 3554

RECEIVED
CENTRAL FAX CENTER
DEC 12 2007


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 09/831,272 Confirmation No. : 3234
Applicant : KIRSCH, Christoph
Filed : August 13, 2001
Group Art Unit : 1633
Examiner : MARVICH, Maria
Docket No. : 9730-001
For : Chimeric Promoters Capable of Mediating Gene Expression in
Plants Upon Pathogen Infection and Uses Thereof

INTERVIEW SUMMARY

MAIL STOP AMENDMENT
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir/Madam:

| |
|--|
| CERTIFICATE UNDER 37 CFR 1.8(a) |
| I hereby certify that this correspondence is being deposited by facsimile to 571-273-8300 addressed to Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on 12/12/07 |
|  |
| Nicholas J. Landau, Registration No. 57.120 |

This paper constitutes the Applicant's Interview Summary as required under 37 C.F.R. § 1.133. The interview occurred telephonically on December 12, 2007. Participating were Examiner Maria Marvich and attorney Nicholas Landau (undersigned). Discussed were the objections to Claims 2, 3, 8, 9, 39, 42, and 43; the enablement rejections of Claims 2, 3, 22, 39, 42, 47, and 49; and the obviousness rejection of Claim 48.

Agreement was reached with regard to the objections to Claims 2, 3, 8, 9, 39, 42, and 43.

It was agreed that the objections to Claims 2 and 3 could be overcome if the preambles to these claims are amended to recite "capable of local gene expression in plants wherein expression is induced by elicitor treatment, pathogen infection, or both."

It was agreed that the objection to Claim 39 could be overcome if Claim 39 is amended into independent form.

{WP457732,1}

U S Application No. 09/831,272
Summary of December 12, 2007 Interview

Attorney Docket No. 9730-001

It was agreed that the objection to Claim 42 could be overcome if Claim 42 is amended to replace "the said" with "the."

It was agreed that the objection to Claim 43 could be overcome if Claim 43 is amended to recite "...wherein ~~at least one of the said~~ two or more *cis*-acting elements..."

Agreement was reached with regard to the enablement rejections of Claims 2, 3, 22, 39, 42, 47, and 49. The Examiner stated that Claims 8 and 9 should have been included in the rejection. The Applicant acknowledged the omission. It was agreed that the rejections could be overcome if the claims are limited to *cis*-acting elements "sufficient to direct pathogen-elicitor-specific expression" or "sufficient to direct: pathogen-elicitor-specific expression of a nucleic acid sequence, pathogen-infection-specific expression of a nucleic acid sequence, or both."

No agreement was reached with regard to the obviousness rejection of Claim 48.

Agreement was reached on allowable form of the claims.


U.S. Application No. 09/831,272
Summary of December 12, 2007 Interview

Attorney Docket No. 9730-001

Applicant is grateful for the opportunity to speak with the Examiner regarding this matter. Applicant requests this Summary be entered into the record in compliance with 37 C.F.R. § 1.133. The Examiner is encouraged to contact the undersigned telephonically should there be any further concerns regarding the allowability of this Application.

Respectfully submitted,

AKERMANTENTERFITT
Esperante Building
222 Lakeview Avenue, Suite 400
West Palm Beach, Florida 33401-6183
(516) 653-5000


Nicholas J. Landau, Ph.D.
Registration No. 57,120

Date: December 12, 2007